Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|June 3, 2026

The BioPharm Brief: RNA Editing, Cardiac Remodeling, Rare Disease Gene Therapy

Daily biopharma update covering RNA exon editing licensing, gene therapy clinical data, and preclinical rare disease collaboration advances across the biotech sector.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today we’re looking at advances in RNA editing technology, new cardiac gene therapy data, and a fresh preclinical collaboration in rare genetic disease.

First, Eli Lilly has entered a licensing agreement with Ascidian Therapeutics to access its RNA exon editing platform aimed at inherited kidney diseases. The collaboration highlights growing interest in RNA-based approaches that can modify transcripts without altering DNA. The platform is designed to correct disease-causing mutations at the RNA level, potentially offering a more precise and reversible therapeutic strategy. Lilly’s move signals continued expansion into genetic medicine and reinforces industry momentum around next-generation RNA editing technologies for rare and chronic kidney disorders.

Next, Tenaya Therapeutics reported interim data from its TN-201 gene therapy program targeting MYBPC3-associated hypertrophic cardiomyopathy. The early findings suggest consistent signs of cardiac remodeling along with reductions in disease-related biomarkers. While still in development, the data support continued evaluation of TN-201 as a potential one-time gene therapy for a genetic form of heart disease. The results add to growing clinical interest in gene replacement strategies for cardiomyopathies driven by single-gene mutations.

Finally, a new preclinical collaboration has been announced focused on EHMT1 gene therapy for Kleefstra syndrome, a rare neurodevelopmental disorder. The effort aims to explore therapeutic strategies that could restore or compensate for EHMT1 gene function. While still at an early stage, the collaboration reflects increasing investment in gene therapies targeting ultra-rare conditions with high unmet need. Researchers will work to establish proof-of-concept data to support future development.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • RNA exon editing continues gaining traction through major licensing deals in genetic medicine.
  • Early TN-201 data suggest potential cardiac remodeling benefits in genetic cardiomyopathy.
  • Preclinical EHMT1 collaboration highlights growing focus on ultra-rare disease gene therapies.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more